Basic psychopharmacology of antidepressants, Part 1: Antidepressants have seven distinct mechanisms of action

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL.4, 1998, Pages 5-14

  Stahl, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; MIRTAZAPINE; NEFAZODONE; NORADRENALIN; SEROTONIN; VENLAFAXINE;

DEPRESSION; DOPAMINE BRAIN LEVEL; ELECTROCONVULSIVE THERAPY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPOTHESIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUPROPION; CYCLOHEXANOLS; DOPAMINE; HUMANS; MIANSERIN; MONOAMINE OXIDASE INHIBITORS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; RECEPTORS, NEUROTRANSMITTER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; TRIAZOLES;

EID: 0031917424     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Stahl SM. Essential Psychopharmacology. New York, NY: Cambridge University Press; 1996
2. Stahl SM. Psychopharmacology of Antidepressants. London, England: Dunitz Press; 1997
3. Heninger GR. Indoleamines: the role of serotonin in clinical disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:471-482
4. Brown SL, Bleich A, van Praag HM. The monoamine hypothesis of depression: the case for serotonin. In: Brown SL, van Praag HM, eds. The Role of Serotonin in Psychiatric Disorders. New York, NY: Brunner/ Mazel; 1991:91-128
5. Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:933-944
6. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
7. Barker EL, Blakely RD. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:321-334
8. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-162
9. de Montigny C, Pineyo G, Chaput Y, et al. Electrophysiological studies on the effects of long term reuptake inhibition on the function of 5HT neurons. Clin Neuropharmacol 1992;115(suppl 1A):440A-441A
10. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38:1160-1180
11. Charney DS, Delgade PL, Price LH, et al. The receptor sensitivity hypothesis of antidepressant action: a review of antidepressant effects on serotonin function. In: Brown SL, van Praag HM, eds. The Role of Serotonin in Psychiatric Disorders. New York, NY: Brunner/Mazel; 1991:27-56
12. Sambunaris A, Keppel Hesselink J, Pinder R, et al. Development of new antidepressants. J Clin Psychiatry 1997;58(suppl 6):40-53
13. Richelson E. Pharmacology of antidepressants in use in the United States. J Clin Psychiatry 1982;43:(11, sec.2):4-11
14. Feighner JP, Boyer WF. Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. Chichester, England: John Wiley & Sons; 1996
15. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S-35S
16. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-224
17. Blier P, Lista A, de Montigny C. Differential properties of pre-and post-synaptic 5-hydroxytryptamine 1A receptors, I: effect of spiperone. J Pharmacol ExpTher 1993;265:7-15
18. Blier P, Lista A, de Montigny C. Differential properties of pre-and postsynaptic 5-hydroxytryptamine 1A receptors. II: effect of pertussis and cholera toxins. J Pharmacol Exp Ther 1993;265:16-23
19. Chaput Y, de Montigny C, Blier P. Effects of a selective 5HT reuptake blocker, citalopram, on the sensitivity of 5HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1986;333:342-348
20. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiological study in the rat. Neuropsychopharmacology 1991;5:19-29
21. de Montigny C, Pineyro G, Chaput Y, et al. Electrophysiological studies on the effects of long term reuptake inhibition of the function of 5HT neurons. Clin Neuropharmacol 1992;15(suppl 1A):440A-441A
22. Rutter JJ, Gundiah C, Auerbach SB. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci Lett 1994;171:183-186
23. Wong DT, Bymaster FP, Engleman EA. Presynaptic regulation of extracellular serotonin concentrations in brain. In: Takada A, Curzon G, eds. Serotonin in the Central Nervous System and Periphery. Amsterdam, The Netherlands: Elsevier Science; 1995:3-13
24. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5HT in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992;229: 101-103
25. Bel N, Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993;15: 243-245
26. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. In press
27. Stahl SM. Is serotonin receptor down regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol Bull 1994;30: 39-43
28. Peroutka SJ, Snyder SH. Long term antidepressant treatment lowers spiroperidol labelled serotonin receptor binding. Science 1980;210:88-90
29. Aghajanian GK. Electophysiology of serotonin receptor subtypes and signal transduction pathways. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:451-460
30. Brown SL, van Praag HM. The Role of Serotonin in Psychiatric Disorders. New York, NY: Brunner/Mazel; 1991
31. Cowen PJ. Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 1991;159(suppl 12):7-14
32. Dubovsky SL. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994;55(2, suppl):34-44
33. Glennon RA, Dukat M. Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:415-430
34. Jacobs BL, Fornal CA. Serotonin and behavior: a general hypothesis. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995;461-470
35. Keppel Hesselink JM, Sambunaris A. Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. International Review of Psychiatry 1995;7:41-54
36. Kunovac JL, Stahl SM. Biochemical pharmacology of serotonin receptor subtypes: hypothesis for clinical applications of selective serotonin ligands. International Review of Psychiatry 1995;7:55-68
37. Leysen JE. 5HT2 receptors: location, pharmacological, pathological and physiological role. In: Langer SZ, Brunello N, Racagni G, et al, eds. Serotonin receptor subtypes: pharmacological significance and clinical implications. Basel, Switzerland: Karger; 1992:31-44
38. Leonard BE. Subtypes of serotonin receptors: biochemical changes and pharmacological consequences. Int Clin Psychopharmacol 1992;7:13-21
39. Risch SC, Nemeroff CB. Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry 1992;53(10, suppl):3-7
40. Sandler ML, Coppen A, Harnett S. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. Oxford, England: Oxford University Press; 1991
41. Shih JC, Chen K J-S, Gallaher TK. Molecular biology of serotonin receptors: a basis for understanding and addressing brain function. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress; New York, NY: Raven Press: 1995:407-414
42. Arzmitia EF, Whitaker-Arzmitia PM. Anatomy, cell biology, and plasticity of the serotonergic system: neuropsychopharmacological implications for the actions of psychotropic drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:443-450
43. Dillon KA. Autoradiographic analysis of serotonin 1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res 1991; 554:56-64
44. Mansour A, Chalmers DT, Fox CA, et al. Biochemical anatomy: insights into the cell biology and pharmacology of neurotransmitter systems in the brain. In: Schatzberg A, Nemeroff CB, eds. Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:45-64
45. Marsden CA. The neuropharmacology of serotonin in the central nervous system. In: Feighner JP, Boyer WF, eds. Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. Chichester, England: John Wiley & Sons; 1996:1-34
46. Murphy DL. An overview of serotonin neurochemistry and neuroanatomy. In: Sandler ML, Coppen A, Harnett S, eds. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. Oxford, England: Oxford University Press; 1991:23-36
47. Lesch KP, Aulakh CS, Murphy DL. Serotonin receptor heterogeneity and subsystem complexity: implications for clinical neuropsychopharmacology. Neurology and Psychiatry Brain Research 1993;1:163-172
48. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the brain. I: serotonin 1 receptors. Brain Res 1985;346: 205-230
49. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the brain, II: serotonin 2 receptors. Brain Res 1985;346: 231-249
50. Radja F, Daval G, Hamon M, et al. Pharmacological and physiochemical properties of pre-versus postsynaptic 5-hydroxy-tryptamine 1A receptor binding sites in the rat brain: quantitative autoradiographic study. J Neurochem 1992;58:1338-1346
51. Palacios JM, Waeber C, Mengod G, et al. Molecular neuroanatomy of 5HT receptors. In: Fozard JR, Saxena PR, eds. Serotonin: Molecular Biology, Receptors and Functional Effects. Basel, Switzerland: Birhauser; 1991: 5-20
52. El Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors: relevance to treatment of obsessive compulsive disorder. Neuropsychopharmacology 1995;13:117-127
53. Adell A, Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5HT in raphe nuclei and frontal cortex: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1991;343:237-244
54. Artigas F. 5HT1A receptor antagonists in combination therapy: 5HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 1993;14:262-270
55. Baxter LR, Schwartz JM, Phelps ME. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 1989;46:243-250
56. Foote SL, Morrison JH. Development of the noradrenergic, serotonergic and dopaminergic innervation of neocortex. Curr Top Dev Biol 1987;21: 391-423
57. Frankfurt M, McKittrick CR, Luine VN. Short-term fluoxetine treatment alters monoamine levels and turnover in discrete brain nuclei. Brain Res 1994;650:127-132
58. Fuller R. Mini-review: uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 1994;55:163-167
59. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992;584:322-324
60. Jordan S, Dramer GL, Zukas PK, et al. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 1994;18:294-297
61. Lewis DA, Campbell MJ, Foote SL, et al. The monoaminergic innervation of primate neocortex. Human Neurobiology 1986;5:181-188
62. Morrison JH, Foote SL. Noradrenergic and serotonergic innervation of cortical and thalamic visual structures in old and new world monkeys. J Comp Neurol 1986;243:117-138
63. Morrison JH, Foote SL, Lewis DA, et al. Regional and laminar patterns of monoamine innervation of primate neocortex. In: Sandler M, Dahlstrom A, Belmaker RH, eds. Progress in Catecholamine Research, part B: Central Aspects. New York, NY: Alan Liss: 1988:193-198
64. Rutter JJ, Auerbach SB. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J Pharmacol Exp Ther 1993;265:1319-1324
65. Mann JJ, Malone KM, Diehl DJ, et al. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am J Psychiatry 1996;153:174-182
66. Baxter LR, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive compulsive disorder. Arch Gen Psychiatry 1992;49:681-689
67. Baxter LR, Schwartz JM, Guze BH, et al. Neuroimaging in obsessive compulsive disorder: seeking the mediating neuroanatomy. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive Compulsive Disorders: Theory and Management. 2nd ed. Chicago, Ill: Year Book Medical Publishers; 1990:167-188
68. Gorman J, Liebowicz MR, Fyer AJ. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 1989;150:1480-1484
69. Nordahl TE, Semple WE, Gross M. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 1990;3: 261-272
70. Casper RC. Biology of eating disorders. In: Schatzberg A, Nemeroff CB, eds. Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:557-574
71. Curzon G. 5-hydroxytryptamine in the control of feeding and its possible implications for appetite disturbance. In: Sandler ML, Coppen A, Harnett S. eds. 5-Hydroxytryptamine in Psychiatry: A Spectrum of Ideas. Oxford, England: Oxford University Press; 1991:279-302
72. Grigsnaschi G, Mantelli B, Samanin R. The hypophagic effect of restraint stress in rats can be mediated by 5HT2 receptors in the parventricular nucleus of the hypothalamus. Neurosci Lett 1993;152:1036
73. Piji H, Koppeschaar HP, Willekens FL. Effect of serotonin reuptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes Relat Metab Disord 1991;15:237-242
74. Walsh BT, Devlin MJ. Psychopharmacology of anorexia nervosa, bulimia nervosa and binge eating. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1581-1590
75. Stahl SM. Are two antidepressant mechanisms better than one? J Clin Psychiatry 1997;58:339-341
76. Balon R. The effects of antidepressants on human sexuality: diagnosis and management update 1996. Primary Psychiatry 1997;4:32-48
77. Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders. CNS Drugs 1994;2:78-86
78. Segraves RT. Treatment-emergent sexual dysfunction in affective disorder: a review and management strategies. J Clin Psychiatry Monograph 1993; 11(1):57-60
79. Trickelbank MD. Interactions between dopamine and 5HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 1989;10:127-129
80. Bersani G, Grispini A, Marini S, et al. 5HT2 antagonist ritanserin in neuroleptic induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990;13:500-506
81. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992;50: 1583-1590
82. Marder SR, Van Putten T. Antipsychotic medications. In: Schatzberg A, Nemeroff CB, eds. Textbook of Psychopharmacology. Washington. DC: American Psychiatric Press; 1995;247-262
83. Ballenger JC. Selective serotonin reuptake inhibitors in panic disorder. In: Feighner JP, Boyer WF, eds. Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. Chichester, England: John Wiley & Sons; 1996:155-178
84. Stutzmann JM, Eon B, Darche F, et al. Are 5HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 1991;128:4-8
85. Gillin JC, Jernajczyk W, Valladares-Neto DC, et al. Inhibition of REM sleep by ipsapirone: a 5HT1A agonist. Psychopharmacology Berl 1994; 116:433-436
86. Gillin JC, Sohn WJ, Stahl SM, et al. Ipsapirone, a 5HT1A agonist, suppresses REM sleep equally in depressed patients and normal controls. Neuropsychopharmacology. 1996;15:109-115
87. Seifritz E, Moore P, Trachsel L, et al. The 5HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum analysis similar to 5HT2 blockade. Neurosci Lett 1996;209:41-44
88. Dorsey CM, Lukas SE, Cunningham SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropharmacology 1996;14:437-442
89. Sharpley AL, Williamson DJ, Attenburrow MEJ, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996;126:50-54
90. Bunce K, Tyers M, Beranek P. Clinical evaluation of 5HT3 receptor antagonists as anti-emetics. Trends Pharmacol Sci 1991;12:46-48
91. Costall B, Naylor RJ, Tyers MB. The psychopharmacology of 5HT3 receptors. Pharmacological Therapies 1990;47:181-202
92. Herrstedt J, Sigsaard T, Boesgarrd M. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993;328:1076-1080
93. Levitt M, Warr D, Yelle L. Ondansetron compared with dexamethasone and metclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 1993;328:1081-1084
94. Cooper BR, Wang CM, Cox RF, et al Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropharmacology 1994;11:133-141
95. Breese GR, Cooper BR, Hollister DS. Relationship of biogenic amines to behavior. J Psychiatr Res 1974;11:125-133
96. Casat CD, Pleasants DZ, Schroeder DH, et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull 1989,25:198-201
97. Clay TH, Gualtieri T, Evans RW, et al. Clinical and neuropsychological effects of the novel antidepressant bupropion. Psychopharmacol Bull 1988; 24:143-148
98. Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998;59(suppl 4):66-72
99. Settle EC Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59(suppl 4):32-36
100. Muth EA, Haskins JT, Moyer JA, et al. Antidepressant biochemical profile of the novel bicyclic compound WY-455,030 (venlafaxine), an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497
101. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029
102. Stahl SM. Remeron (mirtazapine): a novel antidepressant that disinhibits serotonin and norepinephrine by alpha-2 antagonism. Psychiatric Annals 1997;27:14-16
103. Stahl SM. Remeron (mirtazapine): designing specific serotonergic actions. Psychiatric Annals 1997;27:138-144
104. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10(suppl 4):11-17
105. DeBoer T, Guist GSF, Berendsen HHG. The alpha-2 selective adrenoceptor antagonist Org 3770 (mirtazapine; Remeron) enhances noradrenergic and serotonergic transmission. Human Psychopharmacology 1995;10: S107-S118
106. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with selective alpha-2 adrenoceptor antagonist effects. Pharmacotherapy 1997;17:10-21
107. Stahl SM, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand 1997;96(suppl 391):22-30